By combining long-standing expertise with new research solutions, Charles River advances drug discovery for treatments of respiratory diseases. Our recently validated rodent models provide rapid, cost-effective methods for evaluating the potential efficacy of novel anti-inflammatory agents targeting COPD or asthma conditions.
To learn more about our wide range of capabilities to support your respiratory research, click here.
Related Information
|
|
|
COPD model, chronic obstructive pulmonary disease model, LPS rat, respiratory model, asthma model, lung inflammation model, Brown Norway rat, asthma, COPD, acute lung, acute lung injury, lung injury, Bleomycin-Induced Pulmonary Fibrosis, Bleomycin-Induced, Pulmonary, Fibrosis, bleomycin
Respiratory Disease Models | Charles River
By combining long-standing expertise with new research solutions, Charles River facilitates drug development in for respiratory diseases.